NFKB1 and osteoporosis: In conclusion, our study illustrated that BHD was capable to inhibit osteoclast formation and function in vitro and in vivo by suppressing ERK, JNK and NF-κB signaling (Figure 6), suggesting that BHD may prove to be a drug candidate for osteoclastogenic sicknesses like glucocorticoid-induced osteoporosis.